ALNYLAM PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-10.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2022-02-10
- ALNYLAM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2019 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2018 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-10 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-14 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |